MINNEAPOLIS, Nov., 9, 2011
/PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device
company that develops, manufactures and markets innovative
proprietary products to treat voiding dysfunctions, today announced
the issuance of United States Patent No. 8,046,082 covering the
stimulator used in the Urgent® PC Neuromodulation System. The
Urgent PC Neuromodulation System is an office-based, non-surgical
system, used to treat overactive bladder syndrome (OAB) and the
associated symptoms of urinary urge incontinence, urinary urgency
and urinary frequency. The new patent covers the reusable Urgent®
PC stimulator. When connected to a thin needle electrode near
the ankle to access the tibial nerve, the stimulator delivers
current to the sacral nerve plexus that controls bladder and pelvic
floor function.
"This newly-issued patent further strengthens our patent
position on the Urgent PC System and reinforces our commitment to
this product," said David Kaysen,
President and CEO of Uroplasty. "We are very pleased that the
United States Patent Office has awarded this apparatus patent on
the unique stimulator used in our Urgent PC System. Our broad
intellectual property portfolio, applicable to the Urgent PC System
and its components, now includes apparatus, method, and system
patents."
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in
The Netherlands and the
United Kingdom, is a medical
device company that develops, manufactures and markets innovative
proprietary products for the treatment of voiding dysfunctions. Our
focus is the continued commercialization of our Urgent® PC
Neuromodulation System, the only FDA-cleared neuromodulation system
that delivers posterior tibial nerve stimulation (PTNS) for the
office-based treatment of overactive bladder and associated
symptoms of urgency, frequency and urge incontinence. We also offer
Macroplastique® Implants, an injectable urethral bulking agent for
the treatment of adult female stress urinary incontinence primarily
due to intrinsic sphincter deficiency. For more information on the
company and its products, please visit Uroplasty, Inc. at
www.uroplasty.com.
For Further
Information:
|
|
|
Uroplasty, Inc.
|
EVC Group
|
|
David Kaysen, President and CEO,
or
|
Doug Sherk/Jenifer Kirtland
(Investors),
415.568.9349
|
|
Medi Jiwani, Vice President,
CFO, Treasurer
|
Chris Gale (Media),
646.201.5431
|
|
952.426.6140
|
|
|
|
|
SOURCE Uroplasty, Inc.